Cleerly ISCHEMIA vs 1CMR Pro
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if your primary objective is to non-invasively determine the likelihood of coronary artery ischemia and characterize coronary plaque from CCTA scans. This tool is ideal for initial diagnostic workups and risk stratification, enabling physicians to personalize treatment plans based on vessel-level ischemia and detailed plaque analysis.
View Cleerly ISCHEMIA →Choose 1CMR Pro if…
Choose 1CMR Pro if you require highly precise, automated, and consistent volumetric and functional measurements from Cardiac MRI scans. This software is best suited for institutions seeking to enhance the accuracy and reproducibility of CMR reporting for detailed cardiac assessment and follow-up, especially when prioritizing local data processing within the hospital's infrastructure.
View 1CMR Pro →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | 1CMR Pro |
|---|---|---|
| Pricing | Contact for details | Contact for pricing |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | On-premise (software installed on hospital's own computer, processing data locally via a secure web-based platform) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA) offers a fully web-based platform with comprehensive interactive reports and explicit integration with PowerScribe via API, which streamlines workflow and reduces manual data entry for physicians. While Tool B (1CMR Pro) provides clinician control with editable contours and local processing, its on-premise deployment might entail more initial IT overhead.
Clinical Value
Cleerly ISCHEMIABoth tools are FDA-cleared and offer significant clinical value. Tool A (Cleerly ISCHEMIA) provides a comprehensive non-invasive assessment of ischemia, plaque, and stenosis from CCTA, with strong prognostic utility demonstrated in large multicenter trials, including predicting future MACE events. Tool B (1CMR Pro) excels in precision for CMR measurements, claiming up to 40% higher precision than manual analysis, but Tool A's broader diagnostic and prognostic capabilities for CAD give it a slight edge.
Pricing & Value
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA) provides more transparency regarding its pricing, including a retail price, a discounted offer, and details on Category I CPT codes and Medicare reimbursement rates, which directly informs its value proposition for providers. Tool B (1CMR Pro) has not publicly disclosed its pricing, making a direct comparison of value difficult.
Enterprise Readiness
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA) explicitly states HIPAA compliance and BAA availability, along with API integration for existing hospital systems like PowerScribe. While Tool B (1CMR Pro) offers local data processing and ISO 27001 certification, its HIPAA compliance is stated as 'likely' rather than explicit, and BAA availability is not explicitly stated, giving Tool A a more definitive advantage in enterprise readiness.
Innovation
Cleerly ISCHEMIABoth tools are highly innovative in their respective fields. Tool A (Cleerly ISCHEMIA) pioneers non-invasive fractional flow reserve (FFR) estimation and comprehensive plaque characterization from CCTA, potentially reducing the need for invasive procedures. Its recognition with multiple 'Best Overall AI Solution' awards highlights its groundbreaking approach. Tool B (1CMR Pro) offers 'super-human' precision in CMR analysis, but Tool A's broader impact on patient care pathways gives it a slight lead.
Support & Docs
Cleerly ISCHEMIACleerly (Tool A) explicitly lists a broader range of publicly accessible resources, including publications, blogs, webinars, patient education, FAQs, and detailed billing guidelines, in addition to contact options for demos. Mycardium AI (Tool B) mentions contact for support and company documents, but lacks the detailed public resources seen with Tool A.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | 1CMR Pro |
|---|---|---|
| Name | Cleerly ISCHEMIA | 1CMR Pro |
| Company | Cleerly | Mycardium AI Limited |
| Description | Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | 1CMR Pro by Mycardium AI is an FDA 510(k) cleared and CE Class IIB cleared AI-enhanced Cardiac MRI reporting software that delivers up to 40% more precise measurements, enabling faster and more consistent cardiac MRI analysis. |
| Imaging Modality Analyzed | CCTA scans | Cardiac MRI (CMR) images |
| Key Analysis Focus | Non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment, 3D digital models of coronary arteries. | Automated volumetric and functional measurements, automated segmentation and quantification of cardiac structure and function, local data processing. |
| Precision Claims | Not specified | Achieves up to 40% higher precision than manual analysis. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and 1CMR Pro.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or 1CMR Pro
Backers
Who funded each tool's parent company.